DRUG TREATMENT OF PRIMARY HYPERALDOSTERONISM
(literature review)
DOI:
https://doi.org/10.11603/1811-2471.2019.v.i4.10786Keywords:
primary hyperaldosteronism, drug treatmentAbstract
Drug and surgical treatment is successfully used in the treatment of primary hyperaldosteronism (PHA), depending on the clinical form of the disease and options for excessive autonomous secretion of aldosterone. Each treatment has its own indications and contraindications. The paper deals with the issues of drug treatment of PHA and individual features of its implementation.
The aim of the study – to learn modern approaches to the goals, tasks and indications for the use of drug treatment of PHA.
Materials and Methods. Data from the world literature on the problem of drug treatment of PHA to clarify modern approaches to determining its volume, effectiveness evaluation was material for the work.
Results and Discussion. It was established that the recommendation of choice is mineralocorticoid receptor antagonists spironolactone and eplerenone. However, in more than 50 % of cases, monotherapy with these drugs is ineffective. The questions of expediency and necessity of combination of these drugs with other medicines, in particular with potassium and thiazide diuretics, blockers of sodium and calcium channels, ACE – I and angiotensin receptors are considered. Attention is paid to the peculiarities of treatment of family forms of PHA types I–IV and the assessment of the adequacy of the treatment used.
Conclusions. Drug treatment of PHA should be clearly individualized, depending on the clinical form and severity of PHA, the features of functional and structural changes in the target organs and systems of the body.
References
Byrd, J.B., Turcu, A.F., & Auchus, R.J. (2018). Primary aldosteronism. pactical approach to diagnosis and management. Circulation, 138, 8, 823-835. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.033597
Calhoun, D.A. (2018). Medical versus surgical treatment of primary aldosteronism. Hypertension, 71, 4, 566-568. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.118.10759
Shidlovskyi, V.O., Shidlovskyi, O.V., Sheremet, M.I., Zhulkevych, I.V., Andreychyn, S.M., Hanberher, I., …, & Futuima, Yu.M. (2019). Laboratory diagnostics of primary hyperaldosteronism and its peculiarities (literature review). J. Med. Life, 12 (3), 215-220. DOI: 10.25122/jml-2019-0073. DOI: https://doi.org/10.25122/jml-2019-0073
Huang, K.H., Yu, C.C., Hu, Y.H., Chang, C.C., Chan, C.K., Liao, S.C., …, & Lin, Y.H. (2019). Targeted treatment of primary aldosteronism – The consensus of Taiwan Society of Aldosteronism. J. Formos. Med. Assoc., 118, (1 part 1), 72-82. DOI: https://doi.org/10.1016/j.jfma.2018.01.006
Funder, J.W., Carey, R.M., Fardella, C., Gomez-Sanchez, C.E., Mantero, F., Stowasser, M., …, & Montori, V.M. (2008). Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab., 93, 9, 3266-3281. DOI: https://doi.org/10.1210/jc.2008-0104
Aronova, A., Fahey, T.J.III, & Zarnegar, R. (2014). Management of hypertension in primary aldosteronism. World J. Cardiol., 6, 5, 227-233. DOI: https://doi.org/10.4330/wjc.v6.i5.227
Uwaifo, G.I. (2018). Primary aldosteronism treatment & management. Retrieved from: https://emedicine.medscape.com/article/127080-treatment/.
Catena, C., Colussi, G.L., & Sechi, L.A. (2015). Treatment of primary aldosteronism and organ protection. Int. J. Endocrinol., 597247. DOI: https://doi.org/10.1155/2015/597247
Rossi, G.P., Pessina, A.C., & Heagerty, A.M. (2008). Primary aldosteronism: an update on screening, diagnosis and treatment. J. Hypertens., 26, 4, 613-621. DOI: https://doi.org/10.1097/HJH.0b013e3282f4b3e6
Kaplan, M. (2008). Primary aldosteronism: an update on screening, diagnosis and treatment. J. Hypertens., 26, 8, 1708-1709. DOI: https://doi.org/10.1097/HJH.0b013e328302ee10
Young, W.F.Jr. (2019). Diagnosis and treatment of primary aldosteronism: practical clinical perspectives Review. J. Internal. Med., 285, 2, 126-148. DOI: https://doi.org/10.1111/joim.12831
Dudenbostel, T., & Calhoun, D.A. (2017). Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. Am. J. Hypertension, 30, 2, 103-109. DOI: https://doi.org/10.1093/ajh/hpw105
Funder, J.W., Carey, R.M., Mantero, F., Murad, M.H., Reincke, M., Shibata, H., …, & Young, W.F.Jr. (2016). The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 101, 5, 1889-1916. DOI: https://doi.org/10.1210/jc.2015-4061
Janmohamed, S., & Bouloux, P.M. The pharmacological treatment of primary aldosteronism. Expert Opin. Pharmacother., 7, 5, 563-573. DOI: https://doi.org/10.1517/14656566.7.5.563
Bloch, M.J., & Basile, J.N. (2011). Spironolactone is more effective than eplerenone at lowering blood pressure in patients with primary aldosteronism. J. Clin. Hypertens. (Greenwich), 13, 8, 629-631. DOI: https://doi.org/10.1111/j.1751-7176.2011.00495.x
Mulatero, P., Monticone, S., Bertello, C., Mengozzi, G., Tizzani, D., Iannaccone, A., & Veglio, F. (2010). Confirmatory tests in the diagnosis of primary aldosteronism. Horm. Metab. Res., 42, 406-410. DOI: https://doi.org/10.1055/s-0029-1246186
Pechère-Bertschi, A., Herpin, D., & Lefebvre, H. (2016). SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism. Ann. Endocrinol. (Paris), 77, 3, 226-234. DOI: https://doi.org/10.1016/j.ando.2016.01.010
Karagiannis, A., Tziomalos, K., Papageorgiou, A., Kakafika, A.I., Pagourelias, E.D., Anagnostis, P., ..., & Mikhailidis, D.P. (2008). Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin. Pharmacother, 9, 4, 509-515. DOI: https://doi.org/10.1517/14656566.9.4.509
Vaidya, A., & Dluhy, R. (2016). Hyperaldosteronism. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK279065/.
Nakano, Y., Yoshimoto, T., Fukuda, T., Murakami, M., Bouchi, R., Minami, I. …, & Ogawa, Y. (2018). Effect of eplerenone on the glomerular filtration rate (GFR) in primary aldosteronism: Sequential changes in the GFR during preoperative eplerenone treatment to subsequent adrenalectomy. Intern. Med., 57, 17, 2459-2466. DOI: https://doi.org/10.2169/internalmedicine.0438-17
Nakano, Y., Yoshimoto, T., Fukuda, T., Murakami, M., Bouchi, R., Minami, I., …, & Ogawa, Y. (2016). Eplerenone improves carotid intimamedia thickness (IMT) in patients with primary aldosteronism. Endocr. J., 63, 3, 249-255.
Karashima, S., Yoneda, T., Kometani, M., Ohe, M., Mori, S., Sawamura, T., …, & Takeda, Y. (2016). Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens. Res., 39, 3, 133-137. DOI: https://doi.org/10.1038/hr.2015.129
Fourkiotis, V., Vonend, O., Diederich, S., Fischer, E., Lang, K., Endres, S., …, & Quinkler, M. (2012). Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur. J. Endocrinol., 168, 1, 75-81.
Yugar-Toledo, J.C., Modolo, R., de Faria, A.P., & Moreno, H. (2017). Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. Vasc. Health Risk Manag., 13, 403-411. DOI: https://doi.org/10.2147/VHRM.S138599
Verdalles, U., García de Vinuesa, S., Goicoechea, M., Macías, N., Santos, A., Perez de Jose, A., ..., & Luño, J. (2015). Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy? Nephrology (Carlton), 20(8), 567-571. DOI: https://doi.org/10.1111/nep.12475
Quinkler, M., & Stewart, P.M. (2010). Treatment of primary aldosteronism. Best Pract. Res. Clin. Endocrinol. Metab., 24, 6, 923-932.
Gritting, G.T., Cole, A.G., Aurecchia, S.A., Sindler, B.H., Komanicky, P., & Melby, J.C. (1982). Amiloride in primary hyperaldosteronism. Clin. Pharmacol. Ther., 31, 1, 56-61. DOI: https://doi.org/10.1038/clpt.1982.9
Kremer, D.K., Boddy, J.J., Brown, D.L., Davies, R., Fraser, A., Lever, F., & Morton, J.J. (1977). Amiloride in the treatment of primary hyperaldosteronism and essential hypertension. Clin. Endocrinol., 7, 2, 151-157. DOI: https://doi.org/10.1111/j.1365-2265.1977.tb01307.x
Uwaifo, G.I., & Sarlis, N.J. (2018). Which medications in the drug class thiazide diuretics are used in the treatment of primary aldosteronism? Medscape.
Hood, S.J., Taylor, K.P., Ashby, M.J., & Brown, M.J. (2007). The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation, 116, 3, 268-275. DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.690396
Gravez, B., Tarjus, A., Jimenez-Canino, R., El Moghrabi, S., Messaoudi, S., Alvarez de la Rosa, D., …, & Jaisser, F. (2013). The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes. PLoS One, 8, 9, e73737. DOI: https://doi.org/10.1371/journal.pone.0073737
Buggey, J., Mentz, R.J., Pitt, B., Eisenstein, E.L., Anstrom, K.J., Velazquez, E.J., & O'Connor, C.M. (2015). A reappraisal of loop diuretic choice in heart failure patients. Am. Heart J., 169, 3, 323-333. DOI: https://doi.org/10.1016/j.ahj.2014.12.009
Nadler, J.L., Hsueh, W., & Horton, R. (1985). Therapeutic effect of calcium channel blockade in primary aldosteronism. J. Clin. Endocrinol. Metab., 60, 5, 896-899. DOI: https://doi.org/10.1210/jcem-60-5-896
Wu, V.C., Wang, S.M., Chang, C.H., Hu, Y.H., Lin, L.Y., Lin, Y.H., …, & Wu, K.D. (2016). Long term outcome of Aldosteronism after target treatments. Sci. Rep., 6, 32103.
Sato, A., & Saruta, T. (2001). Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J. Int. Med. Res., 29, 1, 13-21. DOI: https://doi.org/10.1177/147323000102900103
Morimoto, R., Omata, K., Ito, S., & Satoh, F. (2018). Progress in the management of primary aldosteronism. Am. J. Hypertens, 31, 5, 522-531. DOI: https://doi.org/10.1093/ajh/hpy018
Podzolkov, V.I., & Osadchiy, K.K. (2009). Ingibitory APF v lechenii arterialnoy gipertenzii: fokus na lizinopril [ACE inhibitors in the treatment of hypertension: a focus on Lisinopril]. Ratsional. farmakoterapiya v kardiologii – Rational Pharmacotherapy in Cardiology, 1, 57-62 [in Russian]. DOI: https://doi.org/10.20996/1819-6446-2009-5-1-57-62
Uwaifo, G.I., & Khardori, R. (2018). Which medications in the drug class angiotensin II receptor blockers are used in the treatment of primary aldosteronism? Medscape.
Dluhy, R.G., & Lifton, R.P. (1999). Glucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab., 84, 12, 4341-4344. DOI: https://doi.org/10.1210/jcem.84.12.6256
Halperin, F., & Dluhy, R.G. (2011). Glucocorticoid-remediable aldosteronism. Endocrinol. Metab. Clin. North Am., 40, 2, 333-341. DOI: https://doi.org/10.1016/j.ecl.2011.01.012
Shahrrava, A., Moinuddin, S., Boddu, P., & Shah, R. (2016). A case of glucocorticoid remediable aldosteronism and thoracoabdominal aneurysms. Case Rep. Endocrinol., 2017571. DOI: https://doi.org/10.1155/2016/2017571
Torpy, D.J., Gordon, R.D., Lin, J.P., Huggard, P.R., Taymans, S.E., Stowasser, M., Chrousos, G.P., & Stratakis, C.A. (1998). Familial hyperaldosteronism type II: Description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J. Clin. Endocrinol. Metab., 83, 9, 3214-3218. DOI: https://doi.org/10.1210/jc.83.9.3214
Quack, I., Vonend, O., & Rump, L.C. (2010). Familial hyperaldosteronism I–III. Horm. Metab. Res., 42, 6, 424-428. DOI: https://doi.org/10.1055/s-0029-1246187
Monticone, S., Tetti, M., Burrello, J., Buffolo, F., De Giovanni, R., Veglio, F., …, & Mulatero, P. (2017). Familial hyperaldosteronism type III. J. Hum. Hypertens, 31, 12, 776-781. DOI: https://doi.org/10.1038/jhh.2017.34
Geller, D.S., Zhang, J., Wisgerhof, M.V., Shackleton, C., Kashgarian, M., & Lifton, R.P. (2008). A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab., 93, 8, 3117-3123. DOI: https://doi.org/10.1210/jc.2008-0594
Amar, L., Azizi, M., Menard, J., Peyrard, S., & Plouin, P.F. (2013). Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. J. Hypertens., 31, 3, 624-629. DOI: https://doi.org/10.1097/HJH.0b013e32835d6d49
Bärfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa-Pérez, S., Heckroth, H., …, & Kolkhof, P. (2012). Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem. Med. Chem., 7, 8, 1385-1403. DOI: https://doi.org/10.1002/cmdc.201200081
Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., …, & Zannad, F. (2013). Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J., 34, 31, 2453-2463. DOI: https://doi.org/10.1093/eurheartj/eht187
Kolkhof, P., Nowack, C., & Eitner, F. (2015). Nonsteroidal antagonists of the mineralocorticoid receptor. Curr. Opin. Nephrol. Hypertens., 24, 5, 417-424. DOI: https://doi.org/10.1097/MNH.0000000000000147
Pei, H., Wang, W., Zhao, D., Wang, L., Su, G.H., & Zhao, Z. (2018). The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure. A systematic review and metaanalysis. Medicine, 97, 16, e0254. DOI: https://doi.org/10.1097/MD.0000000000010254
